Diebold Nixdorf's shares fell after its third-quarter results showed steady growth but weaker profitability. The stock trades at $53.80, down from $66.68 before the earnings. Revenue rose 4.8% year on year to $990.9 million, beating analyst estimates of $979.1 million. Adjusted EPS was $1.34 and adjusted EBITDA $127.8 million, both slightly ahead of forecasts. Operating margin fell to 3.9% from 7.8%. The company cut its full-year revenue guidance to $3.88 billion at the midpoint from $3.9 billion. It lowered adjusted EPS guidance to $4.68, and expects EBITDA of $500 million, below analyst estimates of $524.5 million. Chief executive officer Octavio Marquez blamed high memory component costs and unfavourable product mix. Chief financial officer Thomas S. Timko said 95–98% of contracts should have pricing provisions covering memory costs by year-end.

DBD SHAREHOLDER INVESTIGATION: SueWallSt notifies investors of potential securities claims involving Diebold Nixdorf. Oct 29, 2026, 10:11 ET Diebold Nixdorf's October 28 Form 8-K cut its 2026 free cash flow outlook by up to $65 million and set its prior and revised revenue ranges on different measurement bases. The stock dropped more than 9% at open. NEW YORK, Oct. 29, 2026 /PRNewswire/ - Up to $65 million came off Diebold Nixdorf's (NYSE: DBD) full-year 2026 free cash flow outlook on October 28, 2026, when a Form 8-K filed with the SEC cut the range from $255-$270 million to $190-$210 million, and DBD shares fell as the market reacted. If you bought DBD stock and lost money on today's decline, you may have legal rights. Shareholders who suffered losses are encouraged to submit your DBD loss information now, or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt. The filing indicated that the "revised free cash flow outlook reflects the combined impact of lower expected earnings and working capital requirements. Management remains focused on cash conversion, inventory efficiency and disciplined execution." The same October 28 filing lowered adjusted EBITDA guidance from $510-$535 million to $490-$510 million and adjusted EPS guidance from $5.25-$5.75 to $4.50-$4.85. SueWallSt notifies investors of a pending investigation into potential securities law violations tied to the Company's SEC disclosures to investors. Lost money on Diebold Nixdorf? Request a free review of your DBD losses or call Joseph E. Levi, Esq. at (888) SueWallSt. WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Frequently Asked Questions About the DBD Investigation Q: Who is eligible to participate in the DBD investigation? A: Investors who purchased Diebold Nixdorf (NYSE: DBD) stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares. Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Diebold Nixdorf made materially false or misleading statements regarding its full-year 2026 outlook, including any subsequent reaffirmations or reiterations thereof. When the Company ultimately disclosed significant reductions to its guidance, the stock price declined. Q: Who is conducting the DBD investigation? A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased DBD securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors. Q: What do DBD investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation. Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices. Q: What if I already sold my DBD shares - can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought DBD and sold at a loss may still participate in the investigation. Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval. Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either. Attorney Advertising. Prior results do not guarantee similar outcomes. SOURCE SueWallSt.com